2023: Everything that Got Us Where We Are Now …and How it will Help Us Achieve New Heights

In 2022, our team continued its explosive growth on the back of the many successes we’ve achieved in preformulation, formulation, target product profiles, and helping our clients advance their products into the clinic. We’ve done all these things and more – and our numbers reflect that. It was a fitting way to celebrate our 10^th anniversary as one of the industry’s leading specialty CDMO. 

Day in and day out, we continued meeting our clients’ needs and making them happy – and we did it all during a year in which we expanded into a new 60,000 square foot state-of-the-art facility! This space was a former Cambrex facility. Up until the beginning of 2022, Ascendia occupied half of it and by the end of 2022, we successfully completed our transition into the entire space. We immediately began fitting the building space with the latest technology and equipment. Our metrology teams worked nearly around the clock to ensure we could begin utilizing it as quickly and efficiently as possible to offer sterile and non-sterile manufacturing, as well as clinical trial materials.

Our new facility has allowed us to offer capacity and startup times in a way that virtually no other organization in the specialty CDMO market can offer it right now. Our time to begin a new project remains at about two to three weeks, which - compared to the market average - really shows that we are ahead of the curve for capacity and start times.

But when showcasing what Ascendia has to offer going in to 2023, it is about much more than just our new facilities – it is also about our talented team - working diligently.